Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTB4NE2L)

DOT Name	Leucine-rich repeat transmembrane protein CCDC168 (CCDC168)
Synonyms	Coiled-coil domain-containing protein 168
Gene Name	CCDC168
Related Disease	Gastric adenocarcinoma ( )
UniProt ID	CC168_HUMAN
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Pfam ID	PF15804
Sequence	MSKQYYSFKKGVGSGLEDNTFMTLWDFLESWIIQNDWVAIFFIILLGIIFEIILMKACAS FWKKPTLPEKGSSDVQETEDSCPKSRKLAPENWSVINSSSGERVGTFLEKRITSSLTSEE KECNFEDRILFSREILWSGTSESEDQVSPSSESHVPSSNGISSSLPLFYSEVEETCLSHT EHPDREYETIQFSSKKLFSMMKTNKNKNSGFSSDLSFSASRFTVENEDLDVAPCPLAHLF LSRDQVRLLEENVRNQIPSKPKTKLGSRTTYQCSRSQESLNQNQPSVGMVISVQAQDSFP GQNAFQNQGLYEVQFTSQAQYINHNQESIKSQPESKASNFAQPEDVMKKPFSSSTQDSFQ SQDLDRNQHFVEVPSIVEAKYSVKGLESDEHLGEDQHCVWFIDSNKVKYSIKGQDTIFKN AEFLVLTLNPNLVTEDMPQLRSVKAQGQQQIVSSELNQDSVYSSVPLLSTIKGQKNRRKT PDSKSKLSLNVPSLKAKKTPTSQVFQITVCHTLKNRNELGCKNNTEKKELHERKDISDIA LHLISVSKLILPYVKNYSRKQLVKVMPGLIKCGHFLQKQNKSPDTEKINYAGPLEETGIS DITKKEKEYDKENKRLKNISPKMLPQLEQSFMVNTVQLKAPCLLVETNGKSKESLKDSIT QAKGIGITEFHVLNSKKPFDLHIPKHKTSLEEAISKPMQKLVSSPEMESNNRMKIQEDLQ SSENSHLQLSNGEELPTSTPKTQRCFPRENTQKQKDFLELVLELSNVGLLISPGSKMHKS SEELEAIKIQVNTESVNLKESKPLILNVTEDSDLRESEELECNTGSNITNMHQDKETSDA FHSATYTTISQLPDTETHSISKAKADTLRIIRLSHSASKQEKLPDEKETQNAEYIDKSCT FKKPQQCDRKEQEKEANSELTQGFRFSIHLKQKPKYVKFQMEQISSGSSKAPNKEQEVQP QTLSTQTILENSPCPMMDPFQVEKVKQSTDRPTDRESAGDPKNPLTMPENLPVGELLIET TEYSVPFGGNLQKTTDSHIAEEKEDVKRYLPAVALGSFNNHLLTLPYFKRQEIKKKLSET KSVLSVKYVIMKVKKPAISLMPYINICGTSNHRKKMGGNFEIIIKQILQDKIAAGMLLNV IYPPMSILPNTRMYSRLNAENHSHIKLVQEESQIEREEKYPYFINEGNESQNTLDAKLQD EVKGVKETLPKAVLHDSCNLGLDAHLEKEIKTEKEMHQPIPFTETIIESVVSPIMELSHA ENVKSTQKTQTDCKCTADSETPSPISGKSLIGDPLNQTRESYIPSNGSDTREMGYCFAEE KTEIPKDLPATSPETFNYCTPVLSCSKVMKKRVTFALTTSTAKPKCVNTKAVKPSISETV SVTSHRKKSELDFKTKFKKINQTKGLVPECLNTLCSPMHSRLQREFCLPASQLKQGETAD KTYTDVFAKNSISHDREEKLQDGKEEEHKVLLEAAPQLSQHLGSEAGQMKEIHLESDPVL NCLTLELHINGQRLQHQTGFEQTTLETSLQMGPLEAEELQKANETENDIKVLGGPKIPPP KALQALENSDGLILNAYQKDNELVKSDEELNQPGSTNIQVQPQTHFTQTILKSTSCPTLD QFPFEKVESHVRFSPLKSGEAKVDEIIFYAREGGISSDSSHQKEQAGGTEKKETAIFGSC MPALSTPKTTRNLKQFSDMKTLVNPKCGIIKAKKPSISYMLNIRAGAGPKRRKELSCNLT TKMKELHQGKKGVDETYAFLTMTPDINKYSKVETEKDTLREKRLSSTQVKQDTSPHEDSI TSRDIKETLLQDEEQEERKQEALLKVIPQHLQHFMFRSGQGKDLDFHKLENQGSRKILFV TKQDVPQQLQPAEPIQREETKKCLQTQNGTICTVNSKLLPLKSEDSVNGEVLTGAIKRGV PTDRKCMGEQHNSGKGEKAEFNKDLQATVLELQKSPHGGEAQKANLTDMESGSSNAMNMN VQHEREDKNIQKMLTESVPCYSQHLRFSTHQMKDPDPCKSGSEPKSPEGRSWNLSHIVQK TKQETHFRETVLEPISGYMMKQSPHMQEGIKCMEGLKTSFPKTGKSKIGSIPRDTPWDEN PRRKWDSSISEKTAWNQKNLQTVLKPLDFSSLMSSEYESRSYTLEFIGKKSMSPKCVTLK AKQLRILQLFNIIRYSTENHRKKKQHRFKYKMKGKQWYTSIGEALLSATEYAKSTTSKSM IDKLLYNTAARCILSNRTRRQNLDGHITEEKEEVQENVAAIFLGLLDFFMPVLSDSKNQR NTAQLSEKEIIFNAKCLTMKEKKSSISQIHKINRESTRKHRKKCKSYLKTVSNRKCQENH GHITEEEEEVQENSPATFLGPLDFFMPVLSDSKNQINTIQLSERKIILNPKCLTMKEKKP PISQIHKISGQFTTKHRKKLESNLKTKLKAMWQGENVADTFPNTTSFTPDSSDIKRQSGF QTEIDMRISGLSHTQPTQIESLAEGIARYSDPIDKRRTSNLVKGAKLHDRESGEEKQEHL TEMDPFYAENFMANTYLRKDRHLGKSEDVLLGETFFSKSQIYKGNSEKNVKIEKNKNGKE SLKVGLARMEKSDNCAELSEATDDAISNKYDKQNIGHSVLKENAFCNLAAIVPDSVGRHS PASEEMKRQNGRLKMADRSSPQGRPLQAKQSAVSQSPDTAGYAVVSNNKEQKQNFKAQKT EAEVDLIDQEAKINVAEEFNPESVFFSKIHPLQIENKKEFKTADWKTRADPKTFALPKKQ QELCVSGTIWSYPNPYTSISPKIIRHKDKAKTADVESTMHTKQIKLKAKRITVSQLLEYG TASNKKELRGNIQQQKSFQLSKNAVHRVLKAVYDSGYCVSSIKKLTEVKMEKDKPKDRTC ILPQPKLEKPLKEMQRSLSGCTDMSSILRKQEQDIREKEQKHQSISEDISQYYIGPLRIS SQQINYSSFDAPRIRTDEELEFLIAQRAKEKDVGIAKHSVSIPWEREGSKRLDIPLNSKG QNIFFTELDTSQQKTCQEQELLKQEDISMTNLGSMACPIMEPLHLENTGKVTEEEDVYIN RKISSHVLGKEGLKETDIFVGSKGQKFLCTNSEVQHKVPAEQKEQVNPDHVPESILDSES FLSKDPLHLKQAVNTARKENVTISESFNENLWGKEQSKLDITLKSNRQKMDFSKKLRMKH LSNYYQNKENILESVLPCILHQLYIENPKKEGSAEEIMSSKVLSPMVEKASHEVGIPVDQ PPCSEGIHLNIKGRKEHPQESTHEAFPASVSHSLMDVLQIKSPKVKKALKAINSLGYLTS NTKGIGLLFPRQAEKEEKYTYKALPKPASHSKTDLFQFNASMQQEKLDAMDIPHYDYLTS QTREAVKQMDVIVGYTQNSKKRQDLLKTGQKWQYLPISYENFWEHISCPQKYPCLLQHLM PQEKEALSEGGNLSSRTPGLDLFSADQLSTITKNRLEWIVPLISPRQMKKQDSMLPLGSY HKTIKYASLLFPKGMKSSDGVQVFDLISNNSSPKLRLGKKIETQKANEKVQKEVCLPITL HSLSASMPILQESKGQKDSVEQVIRKGVICHKRRTSKWKKSVFSHILNTSDCGASSNRLE MQWNMTDKMVNVKHRMSEIDLVAAKICESILSLPHFKLNKETIDGVISSNVKSTKQHISQ GKNDRVKAMDMKRIKSPNIILKPRKSSLSHILSIKEFPLLLDIIKQEGKMQEGKGKSSMK LTNLCTSLPSLSHSNSNSRTKAGKDKSGTLKGCLPPLKLQASSNARRVSSAESINRDSLS NVIESKCFPQKKKEDRENIVDVKDVMGLKCITLKGKKSLFRHLLHGKEPQRSNKKLEKMT QEDESNLNVVQNKLCASILSPPHLEWNPRIKEVYMRGITRFCLSSSTQQELSDTMEKCEQ PIDDSLSSIEKAKHMPQKDKDRVEKALEKIMHSKRIALEVKQPSIFQELELNIKEKGGKI QEDKEVEIWSKPFASISFLPYSKVGTIEGEEAMRIKMRSSFSQPNLQESSDTEKTAYEKC ISDNISNSVKKALESILQKEQRQKMEKIRALKKMKSSISQGIQLDIKEQEKRIEHIKGEP SVLLTNACASIPSPSHLQLDTRREKAEYVTEITRYYLPELSHQKSSEAGEKADGVASKGD ITIKVQKAKDYMQQKEDDEVKISAKKDIMHPEDKGLKAKKALSQDLPLNTKEPGKMDQEA QEQGKEDREGEEQGKEDRRGAGQEKVDREDKEQGKMDHEVEEQQKADGVGIEQGKMDGDK NEQERVLFLYLPSNSSLTHYILDTRIEGEEDQQGIIRPGILQPRHQKSSETGKKANGVPS EGDSASEVQKAKDYMQQKEEDEVKISAEKDLMHPEDKDLKGKKALSQNLPLNPKEPGKRD GEGQEQGKEDGEGEEQGNRDGETEEQQQADGVGTEQEKRDGHKSKQETVLFLHLPSESSL TCYELNTRKEGEEDLQGIIKSATLQLRQQKSFDAGKIAHTKSFGVDSSNDVKTVQEYKPQ KEVDRGKTVSVDYIMQPEGTIFEAEQLSLPHTLNIPGSSGSKTREVLTNIKEKLRHVQER KSELDVFLTIPSLSHCKLDKRTAGKKEEQGVTRSFLPPSWHMESSDTGKLKYTLSYLNDI TGDSNRTKYMAQIQKDKANISEKSVMHPEYIAVKAEKSPLSHILKTKELQVNISQQGEKA QEGEVEIVVLLSKTCPFVTSSAFLELDSIKEEEGEPRITRSFMPHLEIQESLPSRQTAPT KPTESLVKKEKQLLPQKEDRVQTVSMHGLMHPNGAVFKAKTSAPPQVFSITEHSPLSKRK EPQWGMKERAGQKQDRTGRPHVILTKTHPFMPSLSHHRFSPSQPKLPISSGAGKSRLANS NEGISSHKVILKANQQMPYKEAKDRVKIEGREGRILPKRIHLRAEALPLALLCNGKNYSL HIEEQGEGVQESKKEPGVVPRKSASFPPPPFYLNCDTRRNEKEGTLGKTQFSFPPLKIQD SSDSGKKAYTESLHGYTLSNSKGPVQPTAQGEEKGGLRIDMEDKMLPKCTDLKAKQLLLS DILNTKKLQWKSKEQKRKIQEDKNKQVKGLPSINTSLLTPPYLKFDTTEGQENVIRIAKV SLPQSRSKESSDAGRIACPEATHGELSSDVKQLKAHLLQKEEKDREKVADMTSVLDPNKM YLKAKKSPVLHTHSFSDLQWKTREQEEEKVQKVKSGPGVMLSKSPSRSSPLHLNVNTGFQ EESIPILTRPSFPLVKLQVSPDTEGGTCIRPIAGDILIYLQKGKHVSQNKEEDDVQIVSI LIFPKHQEEKVQECEGEPGVVLTKSTSLPSLSQLELDKETHLGNEMLRLKRPILRRISHI GETVHRESVVGDIPKDVKNEKQHIPQKEERNQKKIIDMRGTDITLKSKKSPRSCMLHRTE LHVNIGGQGRKEHEGQDKPPGMIQRKMCILFSKPLPSNLKLERATHADEERLGGKTSFVL PLMPSALPDTEKTADAEARSGDVRKGKPHRSQKENRHEVKTIDMRFRIHCQEARISPMSH ILNAKELVLNINKLEKKVHKDKDEACVVLSRTFLSIPSAPPLYLDSGNKTDKDTPGITGS SCPQRTLHVPSNTQKITNRDSVEGVDKNVVKQAEQYVPRPEAEQQLTSNFMISVQQRNQP SRVRSEEDLNQLVLNSRDEDIYFTGFGTIRSGKRPEWLFTGKKAQPVKYKTETLTAFLSY PTMDATKMGGLEEDTEIMDNLNHKISPKASVSLIRKISKELYVTLGTPANSKGFSVSERY AHQQETSSKVSPELAGSCKFDKPKEDGQSNDRISKMFSPKVLAPQTKGSLKKISIVTNWN APQNIEEQDIVMKKQVIRRCEHGHKTRTNTILSKFPLQSGKQKTPSETDVDKKTTAHLSL QMLPGIHMDMTEIDPAKGGRKQALLISEQEEGVLEFLPKSLFPPWTFQFQSGDLEEKHQT DANTNINLEQKKLEMDNDSTVNQKEGKLKIGTNRALHLQEEKTEMHKARTANLEKERGRM DTSSSAHPHLLSLKAEESQMKTQVITHRENSRLIMQKQKKELEASNAKQSIQLQKLFQRN VLDSFYSYVPLSPKRKDQKGRLTIRDLKRELSTKYLTMKIQNHPIPQMLNITGRGTPSNR KKLEYDVKLKNIASWSKDVSGIFIRSLSISIMRSPHTDPKTNLEREKRICLPKFQEKSPN TSEMSKRDTLTIVKGEQNFTNTVPQDPQPFAVDKQQMQKLPNVKSEANLRSEMNKKYLKA QTKERIVPEHDVSRIIKKPDLRIIEQEEKILKRILTPTECPSMLEDPKLPKQRDQSEPVW DMTTQKVQQQKAFPGTVPIPPQVKSSEVKIVADSTNAEHLLPICEATKAISESQVKNMIQ DKVSSDKLDNIQAYKPDDLKSPPFPEGPDTISTAIYPKTQHKSLLEQFTPKEKNKLTSHL ESKALEIQLNLIPEMARKSLQMFNFYPKGTISKDNSWRFYSRHKTMNFMSLEGTDTIEPN SKHKHQKDSPLASNMKTLIVDVSSDSEETITKLQSINKLENGTSAVTSASEMLLPHTLQN HSVKEKGKLLMHFSVKTLEIQMKAFPRIVRESYAMTSAHERKKPLSNCIHPGFTGPKRQN RILLLSEEKSLHQIDLDLQYKYLRFLLGLPVGSTFPKPNVLPKHSKLNTIAVCKNVNAGG QSGSLSIDTELLEQHISFKKQSPHENSSLIRKFPQPTLVCASDRDLHSPRKKDTQVLSES EFHVTPEKNKQYHVWFQERNTCESVDLRTQRNATGSAVSCETQISEDFVDIQTDIESPAD LDECSCLEVSESEECVFLEANSYLSQESENILFELQTGIPLENVYKITTDLKSFYSEDSG SHCTRECRKETLIITPPSCKSHKSRKYRSSSKMKSPDWLCHSSSNTAEIQSRSSSVSFSE EKISWTTKSRTSYSSAPLTESNIKSHLAKNQGKSHRHPESQERKKARSDLFRKNSSHWDH DYSCTHSKGKRDRKKRVYDYESERLDCFQSKHKSASKPHHDDINFYSERKQNRPFFFACV PADSLEVIPKTIRWTIPPETLRKRNFRIPLVAKISSSWNIWSSSKKLLGSLSGSLTTVFH S

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance		REF
Gastric adenocarcinoma	DISWWLTC	Strong	Genetic Variation	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DOT

1 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the mutagenesis of Leucine-rich repeat transmembrane protein CCDC168 (CCDC168).	[2]
------------------------------------------------------------------------------------

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Coumarin	DM0N8ZM	Investigative	Coumarin decreases the phosphorylation of Leucine-rich repeat transmembrane protein CCDC168 (CCDC168).	[3]
------------------------------------------------------------------------------------

References

1	Whole-exome sequencing capture kit biases yield false negative mutation calls in TCGA cohorts.PLoS One. 2018 Oct 3;13(10):e0204912. doi: 10.1371/journal.pone.0204912. eCollection 2018.
2	Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
3	Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.